A Phase 2 interventional study of Lurasidone 80mg tablet in Schizophrenia, sponsored by Sumitomo Pharma America, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-04-17.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 25th largest by enrollment, is one of 2 that started in 2004, is one of 5 in phase 2, and was the 3rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2004.
This study's enrollment of 61 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 28th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2004, is one of 4 in phase 2, and was the 3rd registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
Study will evaluate long-term safety and tolerability of a new compound in the treatment of patients with schizophrenia as assessed by adverse events (AEs), measures of extra pyramidal symptoms (EPS; Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Scale [BAS], and Simpson-Angus Rating Scale [SAS]), vital sign measurements, electrocardiograms (ECGs), clinical laboratory evaluations.
Lurasidone 80mg oral tablet taken once a day
Drug: Lurasidone 80mg tablet
Also known as: Lurasidone
Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study
Time frame: 1 year
| Milestone | Lurasidone 80 mg |
|---|---|
| Started | 61 |
| Completed | 7 |
| Not completed | 54 |
| participants | Lurasidone 80 mg |
|---|---|
| Number of Subjects With an Adverse Events in a One Year Open Label Lurasidone Study | 59 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone 80 mg | — | 12/59 (20.3%) | 18/59 (30.5%) |
| Event | Lurasidone 80 mg |
|---|---|
| SchizophreniaPsychiatric disorders | 8/59 |
| Pericardial EffusionCardiac disorders | 1/59 |
| OrchitisInfections and infestations | 1/59 |
| PneumoniaInfections and infestations | 1/59 |
| SepsisInfections and infestations | 1/59 |
| Cerebrovascular AccidentNervous system disorders | 1/59 |
| Self Injurious BehaviorPsychiatric disorders | 1/59 |
| ProstatitisReproductive system and breast disorders | 1/59 |
| Pulmonary MassRespiratory, thoracic and mediastinal disorders | 1/59 |
| Event | Lurasidone 80 mg |
|---|---|
| NauseaGastrointestinal disorders | 4/59 |
| BronchitisInfections and infestations | 4/59 |
| Weight IncreasedInvestigations | 4/59 |
| SedationNervous system disorders | 4/59 |
| VomitingGastrointestinal disorders | 3/59 |
| NasopharyngitisInfections and infestations | 3/59 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/59 |
| Weight DecreasedInvestigations | 3/59 |
| Age, Continuous(years) | Lurasidone 80 mg |
|---|---|
| Mean | 41.3 ± 11.05 |
| Sex: Female, Male(Participants) | Lurasidone 80 mg |
|---|---|
| Female | 15 |
| Male | 44 |
| Region of Enrollment(participants) | Lurasidone 80 mg |
|---|---|
| United States | 59 |
The record gives a start of Jul 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →